195 related articles for article (PubMed ID: 29866600)
1. Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy.
Tarek MM; Shafei AE; Ali MA; Mansour MM
Biomed J; 2018 Apr; 41(2):118-128. PubMed ID: 29866600
[TBL] [Abstract][Full Text] [Related]
2. Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
Saito K; Nakayama E; Valmori D
PLoS One; 2016; 11(3):e0150623. PubMed ID: 26937656
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
[TBL] [Abstract][Full Text] [Related]
4. HLA-DRB1*0410-restricted recognition of XAGE-1b37-48 peptide by CD4 T cells.
Morishita Y; Uenaka A; Kaya S; Sato S; Aji T; Nakayama E
Microbiol Immunol; 2007; 51(8):755-62. PubMed ID: 17704638
[TBL] [Abstract][Full Text] [Related]
5. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
Zhou Q; Guo AL; Xu CR; An SJ; Wang Z; Yang SQ; Wu YL
Clin Exp Immunol; 2008 Sep; 153(3):392-400. PubMed ID: 18803763
[TBL] [Abstract][Full Text] [Related]
6. XAGE-1 expression in non-small cell lung cancer and antibody response in patients.
Nakagawa K; Noguchi Y; Uenaka A; Sato S; Okumura H; Tanaka M; Shimono M; Ali Eldib AM; Ono T; Ohara N; Yoshino T; Yamashita K; Tsunoda T; Aoe M; Shimizu N; Nakayama E
Clin Cancer Res; 2005 Aug; 11(15):5496-503. PubMed ID: 16061866
[TBL] [Abstract][Full Text] [Related]
7. In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.
Herrera LRM
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2297-2306. PubMed ID: 32856858
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.
Kikuchi E; Yamazaki K; Nakayama E; Sato S; Uenaka A; Yamada N; Oizumi S; Dosaka-Akita H; Nishimura M
Cancer Immun; 2008 Aug; 8():13. PubMed ID: 18752338
[TBL] [Abstract][Full Text] [Related]
9. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells.
Shimono M; Uenaka A; Noguchi Y; Sato S; Okumura H; Nakagawa K; Kiura K; Tanimoto M; Nakayama E
Int J Oncol; 2007 Apr; 30(4):835-40. PubMed ID: 17332921
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants of immunoglobulin γ and κ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.
Pandey JP; Namboodiri AM; Ohue Y; Oka M; Nakayama E
Clin Exp Immunol; 2014 Apr; 176(1):78-83. PubMed ID: 24304136
[TBL] [Abstract][Full Text] [Related]
11. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma.
Talebian Yazdi M; Loof NM; Franken KL; Taube C; Oostendorp J; Hiemstra PS; Welters MJ; van der Burg SH
Cancer Immunol Immunother; 2015 Sep; 64(9):1109-21. PubMed ID: 26025564
[TBL] [Abstract][Full Text] [Related]
12. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
13. Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing.
Batool S; Bin-T-Abid D; Batool H; Shahid S; Saleem M; Khan AU; Hamid A; Mahmood MS; Ashraf NM
Expert Opin Biol Ther; 2021 Nov; 21(11):1525-1533. PubMed ID: 34547976
[TBL] [Abstract][Full Text] [Related]
14. Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma.
Ali Eldib AM; Ono T; Shimono M; Kaneko M; Nakagawa K; Tanaka R; Noguchi Y; Nakayama E
Int J Cancer; 2004 Feb; 108(4):558-63. PubMed ID: 14696120
[TBL] [Abstract][Full Text] [Related]
15. Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors.
Sato S; Noguchi Y; Ohara N; Uenaka A; Shimono M; Nakagawa K; Koizumi F; Ishida T; Yoshino T; Shiratori Y; Nakayama E
Cancer Immun; 2007 Mar; 7():5. PubMed ID: 17335148
[TBL] [Abstract][Full Text] [Related]
16. Reverse Vaccinology Approach in Constructing a Multi-Epitope Vaccine Against Cancer-Testis Antigens Expressed in Non-Small Cell Lung Cancer.
Herrera LRM
Asian Pac J Cancer Prev; 2021 May; 22(5):1495-1506. PubMed ID: 34048178
[TBL] [Abstract][Full Text] [Related]
17. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
18. Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches.
Mahdevar E; Safavi A; Abiri A; Kefayat A; Hejazi SH; Miresmaeili SM; Iranpur Mobarakeh V
J Biomol Struct Dyn; 2022 Sep; 40(14):6363-6380. PubMed ID: 33599191
[TBL] [Abstract][Full Text] [Related]
19. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers.
Egland KA; Kumar V; Duray P; Pastan I
Mol Cancer Ther; 2002 May; 1(7):441-50. PubMed ID: 12479262
[TBL] [Abstract][Full Text] [Related]
20. In Silico-Guided Sequence Modification of Epitopes in Cancer Vaccine Development.
Hoo WPY; Siak PY; In LLA
Methods Mol Biol; 2020; 2131():213-228. PubMed ID: 32162256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
